BioSpace Insights
The BioSpace Insights team performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.
Latest from Insights
Taking an early proof of concept into preclinical and clinical development is a costly and complex process. But there are strategic ways to streamline the process and reduce risk and costs. In this webinar, you’ll hear directly from Nobel Laureate Sir Michael Houghton and experts from Applied Pharma, who bring decades of real-world success and deep scientific expertise.
Listen to Denatured
Unravel the business of science with BioSpace.
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe and Jennifer Fakish at Danaher Corporation. They discuss how antibody drug conjugates (ADCs) are transforming cancer care. With AI-powered pathology, doctors can now measure HER2 more precisely to match patients with the best treatments.
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field’s therapeutic horizons.
Upcoming Events
In this webinar, leading oncology experts Dr. Javier Cortés and Dr. Antonio Llombart-Cussac will explore how collaborative-initiated trials are transforming the clinical research landscape and creating new opportunities for scientific and clinical impact.
Monday, March 2, 2026 11am–12pm EST
·
Virtual
Artificial intelligence is rapidly reshaping the life sciences, from automating repetitive tasks to enabling advanced scientific and safety assessments across drugs, biologics, and devices. As adoption grows across regulators, pharmaceutical companies, technology developers, nonprofits, and collaborative consortia, the need for clear, risk-based frameworks for validation, governance and human oversight becomes increasingly critical.
Tuesday, March 17, 2026 1–2pm EDT
·
Virtual
Every biopharma R&D and investment decision could be guided by connected intelligence. Join us to hear firsthand how agentic workflows and enterprise-scale data are helping drug developers move faster from molecule to market with greater confidence.
Wednesday, March 18, 2026 11am–12pm EDT
·
Virtual
BioSpace at 2025 SCOPE Summit
- Meeting on the Mesa: October 6-8, 2025 | Phoenix, AZ
Events
In this live panel discussion, speakers focused on the EU AI Act’s global regulatory implications for medical devices & QARA’s future. An executive summary is available.
FROM BIOSPACE INSIGHTS
This week on Denatured, Head of Insights Lori Ellis and guests discuss the persisting challenges of diversity, equity and inclusion when designing clinical trials.
In this second episode of our collaboration with DIA, we discuss the challenging, collaborative process of regulating advanced therapy product development with guests James Wabby, AbbVie and Rob Schulz, Suttons Creek, Inc.
BioSpace’s Lori Ellis discusses the risks and challenges of cell and gene therapy combination products with DIA speakers James Wabby, AbbVie and Rob Schulz, Suttons Creek, Inc.
BioSpace’s third report on diversity, equity, inclusion and belonging in life sciences examines dramatic shifts in attitude around diversity initiatives.
In the second episode of our series on women’s health, we discuss what may happen to future generations if women, the custodians of generational health, are not comfortable sharing complete medical histories.
Takeda Oncology US Head of Sales, Annette Montandon, discusses how embodying a patient-first approach is key to the success of colorectal cancer drug FRUZAQLA®.
Federal funding and legislation spotlight women’s health opportunities and challenges.
The pharmaceutical industry is facing critical attention, particularly around drug pricing and development costs. Drug development cost is about 10% of the total healthcare spend in the United States. Broader issues such as local monopolies, utilization, unit, and costs and local monopolies, politics and a fragmented payer system contribute to the increasingly high costs to patients.
This week, we’re talking money! Following the release of BioSpace’s 2024 Salary Report, we discuss salary trends and how they are impacting the biopharma workforce.
GenAI, the youngest of the AI family, is evolving quickly. The global life sciences industry is attempting to evolve with it. However, as a keynote session at DIA’s MASC suggests, taking a pause to understand AI risks and to prepare to comply with the EU AI Act is what is needed.